BR112022003143A2 - Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i. - Google Patents

Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i.

Info

Publication number
BR112022003143A2
BR112022003143A2 BR112022003143A BR112022003143A BR112022003143A2 BR 112022003143 A2 BR112022003143 A2 BR 112022003143A2 BR 112022003143 A BR112022003143 A BR 112022003143A BR 112022003143 A BR112022003143 A BR 112022003143A BR 112022003143 A2 BR112022003143 A2 BR 112022003143A2
Authority
BR
Brazil
Prior art keywords
binds
lgr5
egfr
antibody
topoisomerase inhibitor
Prior art date
Application number
BR112022003143A
Other languages
English (en)
Inventor
Isaac Wasserman Ernesto
Mark Throsby
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of BR112022003143A2 publication Critical patent/BR112022003143A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i. a invenção descreve anticorpos ou partes funcionais, derivados e/ou análogos dos mesmos que compreendem um domínio variável que se liga a uma parte extracelular do egfr e um domínio variável que se liga a uma parte extracelular do lgr5 para uso no tratamento de câncer, sendo que o anticorpo ou parte funcional, derivado e/ou análogo do mesmo é administrado com um inibidor de topoisomerase i.
BR112022003143A 2019-08-19 2020-08-19 Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i. BR112022003143A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19192327 2019-08-19
PCT/NL2020/050517 WO2021034194A2 (en) 2019-08-19 2020-08-19 Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor.

Publications (1)

Publication Number Publication Date
BR112022003143A2 true BR112022003143A2 (pt) 2022-05-17

Family

ID=67659296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003143A BR112022003143A2 (pt) 2019-08-19 2020-08-19 Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i.

Country Status (11)

Country Link
US (1) US20230084382A1 (pt)
EP (1) EP4017879A2 (pt)
JP (2) JP2022545457A (pt)
KR (1) KR20220048015A (pt)
CN (2) CN116333154A (pt)
AU (1) AU2020331879A1 (pt)
BR (1) BR112022003143A2 (pt)
CA (1) CA3151641A1 (pt)
IL (1) IL290247A (pt)
MX (1) MX2022002096A (pt)
WO (1) WO2021034194A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240207457A1 (en) * 2021-05-11 2024-06-27 The Catholic University Of Korea Industry-Academic Cooperation Foundation Cancer-specific polypeptide and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
ATE322265T1 (de) * 2000-05-15 2006-04-15 Celgene Corp Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
HUE057994T2 (hu) 2008-06-27 2022-06-28 Merus Nv Antitesttermelõ, transzgenikus, egérfélékhez tartozó állat
CN102356092B (zh) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
CN108026174B (zh) 2015-07-10 2023-02-17 美勒斯公司 人cd3结合抗体
CN108602888B (zh) * 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
AU2017239038B2 (en) * 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody

Also Published As

Publication number Publication date
IL290247A (en) 2022-03-01
EP4017879A2 (en) 2022-06-29
JP2022545457A (ja) 2022-10-27
CN114555115A (zh) 2022-05-27
MX2022002096A (es) 2022-03-17
CA3151641A1 (en) 2021-02-25
AU2020331879A1 (en) 2022-02-24
WO2021034194A2 (en) 2021-02-25
JP2024075676A (ja) 2024-06-04
CN116333154A (zh) 2023-06-27
KR20220048015A (ko) 2022-04-19
US20230084382A1 (en) 2023-03-16
WO2021034194A3 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112018014759A2 (pt) derivados de maitansinoide, conjugados dos mesmos e métodos de uso
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
BR112022014189A2 (pt) Conjugado de anticorpo anti-trop-2 análogo de exatecano e uso médico do mesmo
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112019008417A2 (pt) compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
BR112017027246A2 (pt) marcador de indução de degradação de proteína e uso do mesmo
BR112022003282A2 (pt) Glicovariantes de igm
BR112018008900A2 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
BR112022003143A2 (pt) Tratamento de câncer com uma combinação de um anticorpo que se liga ao lgr5 e ao egfr e um inibidor de topoisomerase i.
BR112015016817A8 (pt) métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica
BR112019003712A2 (pt) composições marcadoras, e métodos para produção e uso das mesmas
BR112022004831A2 (pt) Anticorpos que se ligam a vista em ph ácido
BR112019020412A2 (pt) composições e métodos para detectar câncer de pulmão
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112017027617A2 (pt) tala nasal
CO2021005579A2 (es) Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3